SCHEMBL25173049

SCHEMBL25173049

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](Cc1cc(Br)ccc1C)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.34
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ EDNRB P24530 1/20 0.34
▸ EDNRA P25101 1/20 0.34
▸ CYP1A2 P05177 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ MAPT P10636 5/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27078253 0.89 ALDH1A1 (0.35) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL30510351 0.89 MAPT (0.35) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL30510307 0.89 ALDH1A1 (0.35) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL25173117 0.88 CETP (0.31) CYP1A2
SCHEMBL30767804 0.87 PPARG (0.39) ALDH1A1KMT2AKDM4ECYP1A2LMNA
SCHEMBL25179578 0.87 PPARG (0.39) ALDH1A1KMT2AKDM4ECYP1A2LMNA
SCHEMBL3834577 0.84 MEN1 (0.38) MEN1KMT2ANPC1RAB9A
SCHEMBL3835250 0.84 MEN1 (0.38) MEN1KMT2ANPC1RAB9A
SCHEMBL7412293 0.84 MEN1 (0.38) MEN1KMT2ANPC1RAB9A
SCHEMBL25179512 0.83 PTGES (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS ALDH1A1 4838/4885MEN1 492/4885KMT2A 3145/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS ALDH1A1 4838/4885MEN1 492/4885KMT2A 3145/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS ALDH1A1 4838/4885MEN1 492/4885KMT2A 3145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback